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Abstract
Background: Colorectal cancer is a common malignancy and a leading cause of cancer-related death. Half of patients
with colorectal cancer initially present with non-specific or vague symptoms. In the need for a safe low-cost test, the
immunochemical faecal occult blood test (iFOBT) may be part of the evaluation of such patients in primary care.
Currently, Danish general practitioners have limited access to this test. The aim of this article is to describe a study that
will assess the uptake and clinical use of iFOBT in general practice. Furthermore, it will investigate the diagnostic value
and the clinical implications of using iFOBT in general practice on patients presenting with non-alarm symptoms of
colorectal cancer.
Methods/Design: The study uses a cluster-randomised stepped-wedge design and is conducted in the Central Denmark
Region among 836 GPs in 381 general practices. The municipalities of the Region and their appertaining general
practitioners will be included sequentially in the study during the first 7 months of the 1-year study period. The
following intervention has been developed for the study: a mandatory intervention providing all general practitioners
with a starting package of 10 iFOBTs, a clinical instruction on iFOBT use in general practice and online information
material from the date of inclusion, and an optional intervention consisting of a continuous medical education on
colorectal cancer diagnostics and use of iFOBT.
Discussion: This study is among the first and largest trials to investigate the diagnostic use and the clinical value of
iFOBT on patients presenting with non-alarm symptoms of colorectal cancer. The findings will be of national and
international importance for the future planning of colorectal cancer diagnostics, particularly for ‘low-risk-but-not-no-risk’
patients with non-alarm symptoms of colorectal cancer.
Trial registration: A Trial of the Implementation of iFOBT in General Practice NCT02308384. Date of registration: 26
November 2014
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Background
Colorectal cancer (CRC) is the second most common
type of cancer in Denmark and is a leading cause of
cancer-related death [1, 2]. In Denmark, approx. 25 % of
all new CRC cases in 2013 were diagnosed in stage IV
with a 5-year survival of less than 5 % [3]. Considering
that CRC is a potentially curable disease when found in
earlier stages and that survival is strongly related to stage
at diagnosis, these figures underline the importance of in-
creasing the proportion of CRCs diagnosed in early stage-
s.Several initiatives have been made to support a stage
shift towards earlier diagnosis of CRC. One important step
is screening. Studies show that screening for CRC using
faecal occult blood tests may reduce CRC mortality in
the screened age group [4–6]. Despite the advantages
of screening, 75–80 % of CRC cases must still be found
through symptomatic presentation in general practice
[7, 8]. Therefore, another important strategy has been
to support urgent referral and investigation of patients
with CRC alarm symptoms [9–11]. This initiative pro-
vides the general practitioner (GP) with the opportunity
to refer patients presenting with alarm symptoms of can-
cer to an urgent colonoscopy. Alarm symptoms include
rectal bleeding, change in bowel habits, iron-deficiency
anaemia, weight loss and abdominal pain [12]. However,
the positive predictive values (PPVs) of alarm symptoms
are low (2–8 %). Thus, the GPs must each refer 10–20 pa-
tients with alarm symptoms for further diagnostic workup
to catch one person with CRC [13–15].
Screening and urgent referral for alarm symptoms are
two important improvements of CRC diagnosis. How-
ever, 50 % of CRC cases will present in general practice
with vague or non-specific symptoms that are not eli-
gible for urgent referral [16]. These symptoms are most
often caused by benign conditions and can be consid-
ered as ‘low-risk-but-not-no-risk’ symptoms [17]. Studies
indicate that patients presenting these symptoms may
have a longer diagnostic interval and progress into ad-
vanced cancer stages [18–22]. It is a challenge for the
GP to identify the few CRC cases among all the patients
with similar symptoms, but without CRC. However, a re-
cent study has shown that CRC patients tend to see their
GP more often and have more tests performed than the
average patient in the year preceding a CRC diagnosis
[23]. This may indicate a potential diagnostic window
for early identification of patients with CRC. Thus, tools
that can assist the GP in the diagnostic workup of pa-
tients presenting with uncharacteristic symptoms of
CRC are highly needed.
Immunochemical Faecal Occult Blood Test (iFOBT)
may be one solution to the problem. Unlike the guaiac
faecal occult blood test (gFOBT), which requires three
tests, the iFOBT requires only one test and no pre-test
dietary restrictions are needed as the test uses antibodies
specific to human globin [24]. Furthermore, studies have
found iFOBT to be diagnostically superior to gFOBT
[25, 26]. The diagnostic performance of iFOBT has
mainly been investigated in relation to screening. In
these studies, the sensitivity of iFOBT has generally been
found to be 80–90 %, the specificity to be above 90 %
and the PPV to be better than for most alarm symptoms
(10 %) [26–30]. Only few recent small-scale studies have
investigated the use of iFOBT on symptomatic patients,
and these findings suggest that iFOBT could be benefi-
cial as a case-finding tool in the detection of CRC in
general practice [31–37]. No study has focused on the
use of iFOBT in patients presenting with non-alarm
symptoms of CRC. Large-scale controlled studies are
needed to investigate if and how iFOBT can be used in
the diagnostic workup of symptomatic patients in pri-
mary care. This paper presents a study that implements
iFOBT as a diagnostic tool in general practice in individ-
uals presenting with non-alarm symptoms of CRC.
Methods/Design
Aim
The aims of the study are to:
1. Evaluate the uptake and clinical use of iFOBT in
general practice after targeted courses for GPs in
correct use of the test.
2. Estimate the diagnostic value of iFOBT when used
on patients presenting with non-alarm symptoms of
CRC.
3. Investigate the clinical implications of using iFOBT
for case finding in general practice.
Setting and study population
The study will be performed in the Central Denmark
Region (CDR), which is one of five regions in Denmark.
The CDR covers approx. 1.2 million inhabitants, 381 gen-
eral practices, 836 GPs and 19 municipalities. In each mu-
nicipality, the GPs are organised in units (except for the
GPs in the island municipality of Samsø that are included
in the unit of Aarhus). Each unit is headed by a chairman
who represents the GPs of the municipality. The GPs in
Denmark own their own clinic, and approx. 1550 persons
are listed per GP. Clinics operate as either solo practices
or partnership practices. Remuneration is based on a mix
of capitation (25 %) and fee-for-service (75 %) based on a
centrally negotiated collective agreement. The GP acts as
a gatekeeper to specialised care in the secondary sector,
and the citizens must contact the GP for medical advice
unless in case of emergency. Approx. 10–20 % of all con-
sultations in general practice ends up with a referral [38].
Nearly all citizens (99 %) are listed with a specific general
practice, and the GP is remunerated on the basis of a
contract with Danish Regions and must fulfil certain
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requirements for waiting time and access. iFOBT is
available to Danish GPs only to a limited extent as part
of the urgent referral for non-specific serious symptoms
that might be cancer [39]. However, no logistic setup is
available in general practice regarding ordering and
analysing the test.
The study population constitutes the 836 GPs in the
381 general practices in the CDR and the individuals
aged 30 years or more who are listed with these
practices.
Design
The study uses a cluster-randomised stepped-wedge de-
sign [40]. This design allows us to roll out the study in
large scale and to include all general practices in the CDR.
During the first seven months of the study period,
each municipality and their appertaining GPs will be
randomly and stepwise included in the study to receive
intervention (Fig. 1). The intervention (see details later)
consists of sending iFOBT kits and a clinical guideline
to the GPs and to offer an optional continuous medical
education (CME) session about CRC diagnosis. The invi-
tation to the CME is sent to the chairman of the GP unit
who will arrange the date and time of the meeting. The
month in which the CME is arranged determines the
date of inclusion for each municipality. Thus, the date at
which a municipality is included is defined as the first
working day of the month in which the CME is planned
to be conducted. As the CME component is optional, the
GP units can choose not to participate in the CME. These
municipalities are included on the first working day in the
month after confirmation of non-participation (Fig. 2).
The specific date of the CME is flexibly arranged as the
CME can be scheduled to take place on any of the first 7
months, depending on the preferences of the GPs in the
municipality (in consideration of other arrangements tar-
geting GPs in the municipality, availability of venue, etc.).
Randomisation
The study uses cluster randomisation. The 19 municipal-
ities in the CDR are randomly allocated to monthly
starts of the intervention, ensuring that all municipalities
are included within 7 months. The randomisation is per-
formed prior to initiation of the study and determines
when each cluster is offered to participate in the CME.
The randomisation is blinded to the research group and
is manually performed by two research fellows with no
connection to the project.
Intervention
The intervention was developed using the behavioural
change wheel as analytical framework to identify poten-
tial barriers in the study and to target the intervention
towards specific subjects [41]. Before implementing the
intervention in large scale, we tested and optimised the
intervention in a pilot study among seven general prac-
tices to ensure optimal fit with the GPs’ daily clinical
practice. The process evaluation followed the recom-
mendations provided by the Medical Research Council
(MRC) for evaluation of complex interventions [42]. A
detailed description of the pilot study will be published
in a separate article.
The intervention consists of a mandatory intervention
(for all GPs) and an optional intervention (for GPs that
participate in the CME) (Table 1).
Mandatory intervention
On the date of inclusion, each GP in the included munici-
pality receives a starting package consisting of 10 iFOBT
kits and a clinical instruction on iFOBT use in general
practice and how to order the test through the online
WebReq system. Furthermore, educational material
on CRC diagnostics and use of iFOBT will be avail-
able on a web page announcing relevant news for GPs
(www.praksis.dk). The online material will have links
to the slides from the CME PowerPoint presentation,
the clinical instruction and images of the contents in
the iFOBT kits.
Approx. 1 month after inclusion, participating GPs will
receive a mail containing: status on number of tests re-
quested from their municipality, number and rate of posi-
tive tests, number of general practices in the municipality
that have started using the test and status of the total
number of iFOBTs requested in the CDR. Furthermore,
information on how to get help to get started is provided.
Optional CME intervention
The CME consist of a 45–60 min lecture on CRC diag-
nostics and use of iFOBT in general practice (Table 2).
The CME is an interactive lecture with cases, discussion
and questions based on international literature and guide-
lines and adapted to a Danish general practice setting.
Fig. 1 Stepped-wedge design used for the study. Most municipalities
start out as usual care (C). Within the first seven months, all will cross
over to intervention (I). Seven possible dates of inclusion are available;
the 19 municipalities are randomly distributed between these
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GPs attending the meeting will be registered to facilitate
suitable grouping of CME-attending general practices.
Clinical instruction on iFOBT use in general practice
A clinical instruction was developed for the study
(Table 3). The instruction contains suggested indications
for using the iFOBT and recommended actions on posi-
tive and negative test results. It is aimed for individuals
of 30 years or above with symptoms and signs that could
be related to CRC. However, iFOBT should not be used
on patients presenting alarm symptoms that justify ur-
gent referral to the cancer patient pathway (CPP) [39].
The content is based on published literature.
Suggested indications for iFOBT use
Important symptoms and signs of CRC constitute a con-
tinuum in general practice [39]. Therefore, iFOBT may be
relevant in patients presenting anaemia, change in bowel
habits or abdominal pain when these are not eligible for
urgent referral. Irritable bowel syndrome (IBS) is generally
recommended to be diagnosed using Rome III Criteria
with a minimum of diagnostic testing [43, 44]. However,
as a positive iFOBT is considered equivalent to rectal
bleeding, we found it relevant to recommend performing
an iFOBT on patients undergoing evaluation for IBS.
Finally, non-specific symptoms such as weight loss, loss
of appetite and fatigue are vague symptoms that can be
presented in a vast amount of diseases, including different
cancer types. Thus, using iFOBT as part of the diagnostic
workup of patients presenting non-specific symptoms
may aid the GP in the diagnostic process.
Recommended actions on positive and negative test results
In this study, the iFOBT is used as a ‘rule in test’. An
iFOBT value ≥ 50 μg/L is considered as positive and
should be followed by urgent referral to colonoscopy.
An iFOBT value ≤ 49 μg/L is considered as negative. As
CRC has a low prevalence in general practice, a negative
test result should not exclude CRC; a negative result
should rather serve to guide the GP in the direction of
the most appropriate diagnostic strategy. The iFOBT can
also be repeated.
Analysis of the iFOBT and determination of clinical cut-off
In the Danish screening programme, the iFOBT is ana-
lysed on OC-Sensor DIANA (Eiken Chemical Company,
Ltd, Japan). In the CDR, the analysis is performed at
the Department of Clinical Biochemistry at the Regional
Fig. 2 Flowchart of inclusion date for the participating municipalities
Table 1 Intervention used in the study; a mandatory component for all GPs and an optional component
Content Time
Mandatory intervention Starting package: Date of inclusion
10 iFOBT kits
Clinical instruction on iFOBT use in general practice
Online educational material Date of inclusion
Mail with iFOBT status Approx. one month after inclusion
Optional intervention Continuous medical education (CME) During the first month of inclusion
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Hospital of Randers. All iFOBTs requested from general
practice during the study period will be analysed using this
existing infrastructure in parallel with the screening
samples. iFOBTs are analysed continuously and done
by staff blinded to colonoscopic findings.
Studies of iFOBT cut-off values have primarily been con-
ducted in a screening setting [45–49]. The cut-off value in
the Danish screening programme is set to 100 μg/L. To
our knowledge, no studies have investigated an optimal
cut-off value for patients presenting non-alarm symptoms
of CRC. Small amounts of blood loss in faeces are normal,
but no exact reference level exists [50]. On the other hand,
small amounts of blood in faeces may also be indicative of
CRC. A low cut-off value for blood in stools increases
the number of false positive test results and consequently
the number of performed colonoscopies and required
resources, whereas a high cut-off increases false negative
test results and thereby introduces a risk of delay in the
diagnosis [31, 51]. In this study, we set the cut-off value to
50 μg/L. Thus, a value of <50 μg/L will be considered as
negative and ≥50 μg/L as positive.
Logistics
The iFOBTs will be packed in kits together with a pa-
tient instruction on how to correctly perform an iFOBT,
a paper to facilitate collection of the stool test and a
postage-paid envelope addressed to the Regional Hospital
of Randers. The packing of iFOBT will be provided by a
company with expertise from the screening programme.
The iFOBT kits will be delivered to a regional distributor.
From here, all GPs will get a box with 10 kits at the date
of inclusion. Furthermore, GPs can order additional
iFOBT deliveries during the study period. Thus, the ac-
cess to iFOBT will be easy as the tests will be available
in the GPs’ clinics.
Ordering of an iFOBT is done through WebReq, which
is an online ordering system used by Danish GPs for
requesting laboratory tests. The GP indicates why the
iFOBT is required by ticking a simple box in the ordering
system. It is possible to tick the indications from the
clinical instruction and a space for other symptoms or
signs which can be used if the test is requested on other
indications. The patient’s iFOBT sample is sent to the
Department of Clinical Biochemistry at Randers Regional
Hospital for analysis. Test results are returned to the par-
ticipating GPs electronically and automatically transmitted
to the patient’s medical record.
Outcomes
The uptake and clinical use of iFOBT in general
practice
 Frequency of each indication used for requesting
iFOBT
○ Indications are registered when the GP orders
the test. It is possible to tick the indications from
the clinical instruction, and a box for other
symptoms.
 Rate and frequency of iFOBT use and characteristics
of the patients included.
 The GPs’ action on a positive test result (≥50 μg/L)
○ According to the clinical instruction, a positive
iFOBT result should imply referral to
colonoscopy.
 The GPs’ action on a negative test result (≤49 μg/L)
○ This outcome will evaluate how patients with a
negative test result are followed up.
Table 3 Instructions for using iFOBT in general practice (not
exhaustive, other indications are possible)
Overall indication Individuals aged≥ 30 years with symptoms
and signs of colorectal cancer, but do not
fulfill the criteria of referral in the CPP
Typical indications Change in bowel habitsa
Abdominal paina
Anemia or decrease in hemoglobin >10 %a
Diagnostic workup of patients with IBS
Non-specific symptoms (weight-loss, fatigue,
loss of appetite)b
Actions on test result Positive test (≥50 μg/L)
30–39 years: Referral to colonoscopy with
remark of blood in stools found by iFOBT.
≥40 years: Urgent referral in the cancer
patient pathway for colorectal cancer.
Negative test (≤49 μg/L)
Colorectal cancer cannot be excluded.
aNot eligible for urgent referral in the CPP for CRC
bNot eligible for urgent referral in the CPP for non-specific serious symptoms
Table 2 Programme of the continuous medical education
(CME) of approx. 45–60 min
Welcome
• Introduction of presenters
• Brief introduction to the rational of the study
Presentation, part one: Diagnostics of colorectal cancer in primary care
• Case story
• Update on diagnostics of CRC in today’s general practice
• Why is it important to diagnose CRC in early stages?
Presentation, part two: iFOBT in general practice
• Rational use of iFOBT in general practice
• Indications for using iFOBT
• Actions on test result
• Requesting the test and logistic setup of the study
Questions/discussion
Concluding remarks
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The diagnostic value of using iFOBT in general
practice
 Age- and sex-standardised number and rates of
positive tests (>50 μg/L)
 Overall positive predictive value (PPV) for having
CRC when iFOBT is positive
 PPV of having CRC in relation to iFOBT cut-off
The clinical implications of using iFOBT in general
practice
 Age- and sex-standardised number and rates of
urgent referral in the CPP for CRC
 Age- and sex-standardised number and rates of
colonoscopies
 All findings of colonoscopy on patients with a
positive iFOBT (all ICD-10 codes determined at
colonoscopy)
 Age- and sex-standardised number of CRCs
diagnosed
 Stage distribution of all CRCs diagnosed (I–IV)
Data collection
All citizens in Denmark are registered in the Danish
Civil Registration System with a unique personal identifi-
cation number (CPR number). This identification number
is used in all national registers and enables accurate link-
age between national registers [52]. Statistics Denmark
will provide data on socioeconomic and demographic fac-
tors [53]. Data on iFOBT value and indications for use of
iFOBT will be provided by the Department of Clinical
Biochemistry at Randers Regional Hospital through the
clinical laboratory information system research database
[54]. Data on colonoscopy and comorbidity are extracted
from the Danish National Patient Register [55]. Data on
CRC diagnosis and disease stage are extracted from the
Danish Colorectal Cancer Database.
Sample size
Each included GP is estimated to request 1–2 iFOBTs
per week. This estimate is based on a previous report in-
vestigating Danish citizens’ reasons for encounter with a
GP [56]. When taking into account that the study is
rolled out sequentially and the study period is 1 year, we
expect that 33,600 iFOBTs will be performed during the
study period. Unpublished data from the Danish screen-
ing programme reveal that 6–10 % of performed iFOBTs
are positive (≥100 μg/L) depending on age and gender.
As this study uses a lower cut-off value (50 μg/L) and the
investigated population is symptomatic, we estimate that
approx. 10 % of performed tests will be positive. Screening
studies have shown that the PPV of having CRC when the
iFOBT is positive is approx. 10 % [26, 28, 29]. Therefore,
we estimate that 10 % of the patients with a positive test
will be diagnosed with CRC. In total, we expect to find
approx. 336 CRCs by the use of iFOBT during the study
period. Approx. 800 CRCs are annually diagnosed in the
CDR. Using an alfa of 0.05 and a power of 0.8, we will be
able to show a significant reduction in stage IV cancers
from 25 to 16 % of annual CRC. However, as a reduction
of this scale is unlikely, the study may be underpowered
for this secondary outcome.
Statistical analysis
The study uses a cluster-randomised stepped-wedge de-
sign [40]. Therefore, analysis of data will follow the recom-
mendations for this study design. Each general practice
will serve as a control until crossing over to intervention.
As iFOBT is not available to Danish GPs before they are
included in the study, it will not be possible to compare
the use before and after inclusion. However, we will be
able to evaluate the dissemination of the test in general
practice.
Evaluating the uptake and clinical use of iFOBT in general
practice
The frequency of each indication used to order the
iFOBT will be assessed using descriptive statistics. The
development in rate and frequency of iFOBT use are
assessed descriptively by illustrating the dissemination
with the relation between time and use of iFOBT. One-
way ANOVA is used to test for differences in the develop-
ment of iFOBT use among different municipalities and
among different general practices within each municipal-
ity. To facilitate comparison of the general practices, they
are divided into: clinics where all GPs attended the CME
(all-CME-clinics), clinics where at least one, but not all
GPs, attended the CME (colleague-CME-clinics) and
clinics where no GPs attended the CME (no-CME-clinics).
Actions taken on positive test results are assessed by in-
vestigating if patients with a positive iFOBT have been re-
ferred to colonoscopy. Actions taken on negative test
result are assessed by estimating the rate of patients with a
negative test result that are referred for colonoscopy
and/or has iFOBT repeated.
Estimating the diagnostic value of iFOBT in general practice
The total number of performed iFOBTs is assessed,
and the number and rates of positive tests are calcu-
lated. The overall PPV for CRC in case of iFOBT
values ≥50 μg/L is calculated, and the optimal cut-off
value for the use of iFOBT on patients presenting
non-alarm symptoms of CRC will be investigated by
ROC curves using cut-off intervals of 50 μg/L.
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Investigating the clinical implications of using iFOBT in
general practice
Age- and sex-standardised number and rates of colon-
oscopies and urgent referrals in the CPP are estimated
before and after intervention. Findings by colonoscopy
are identified by ICD-10 codes, and the PPV of finding
serious bowel disease is calculated. Serious bowel dis-
ease is defined as: CRC, inflammatory bowel disease or
adenomas >1 cm. The number of CRCs diagnosed in
the study period is compared with the number of CRCs
diagnosed before introducing iFOBT in general practice.
The same comparison is done for stage distribution of
CRC.
Discussion
To our knowledge, this is among the first and largest
controlled studies on the use of iFOBT in general
practice. The study will investigate the implementation,
diagnostic value and clinical implications of using iFOBT
on patients presenting non-alarm symptoms that could
origin from a CRC. The study is implemented stepwise in
the CDR among 836 GPs in 381 general practices. An
intervention has been developed to optimise implemen-
tation. This study may be an important step towards
improving the diagnostics of CRC in primary care and
detecting CRC in earlier stages.
Only a few small-scale studies have investigated the use
of iFOBT in general practice, and the general conclusion
was that iFOBT may be useful as a diagnostic tool in
general practice [31–37]. However, most studies have
included both alarm symptoms and non-alarm symp-
toms in the evaluation of the test. As many countries
have implemented CPPs to improve CRC diagnostics,
good diagnostic opportunities already exist for patients
presenting with alarm symptoms. However, the CPPs
generally seem to prolong the diagnostic process for pa-
tients presenting with non-alarm symptoms [57]. On
the other hand, all patients presenting symptoms that
could originate from a CRC cannot be referred to col-
onoscopy. Therefore, this study explores the implemen-
tation of iFOBT for patients presenting with non-alarm
symptoms of CRC.
We found it important to develop a clinical instruction
to direct the use of iFOBT in patients presenting with
non-alarm symptoms of CRC. We acknowledge that the
clinical assessment performed by the GP should guide
the exact use. Therefore, the indications presented in the
instruction are suggestions. This implies that GPs can
request iFOBT for other symptoms or signs that they
may find relevant. This gives us the opportunity to ex-
plore if the GPs’ needs for the test are in line with the
indications in the clinical instruction. The criteria for
urgent referral in a CPP are evidently not definite, eg
change in bowel habits can be of different levels of
severity and could be a symptom of many different dis-
eases. Furthermore, the threshold for referring patients
on the basis of a given alarm symptom might be lower
for some GPs than for others. Consequently, we decided
to include anaemia, change in bowel habits and abdominal
pain in the clinical instruction. This is supported by a
recent update of the guideline provided by the National
Institute for Health and Care Excellence (NICE) [58].
However, it is important to underline that performance
of the iFOBT in this study only consider individuals
who are not eligible for urgent referral in the CPP for
CRC. Giving GPs the possibility of performing iFOBT
on ‘low-risk-but-not-no-risk’ patients may result in
more complete and timely diagnostic workup.
Using a cluster-randomised stepped-wedge study design
allows inclusion of all GPs in the CDR. Using municipal-
ities as clusters implies that all GPs in a given municipality
are included at the same time. Thereby, we prevent that
some GPs in the municipality are able to order the test,
while others are not. Furthermore, this setup provides the
opportunity of arranging the CME at a meeting for all
GPs in the municipality. This allows GPs to meet and
discuss the study with colleagues from their own clinical
environment.
Using iFOBT in patients who present non-alarm symp-
toms of CRC may imply faster and earlier diagnosis. This
study constitutes a thorough large-scale investigation of
iFOBT in a real-life setting in general practice. The study
design enables generalisability to other primary-care
settings and will nationally and internationally be very
important in deciding future recommendations for diag-
nostic workup of patients presenting symptoms of CRC.
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